Background Primary HPV testing for cervical cancer screening (HPV-CSS) could result in significant CSS programme changes including extended screening intervals, later age to start of screening and use of a test for a sexually acquired infection. We examine the predictors of women’s intentions to undergo HPV-CSS compared to screening with Pap smears in different screening scenarios.

Methods Participants from a Canadian trial of primary HPV CSS completed a survey which determined women’s intentions to attend CSS in three different models - (a): HPV-CSS conducted annually; (b): HPV-CSS conducted every 4 years; and (c): HPV-CSS conducted every 4 years and starting after age 25. Demographic and health data were assessed, and scales for attitudes about HPV testing (AT), perceived behavioural control (PBC) and direct and indirect subjective norms (SND, SNI) were created. Three logistic regression models were created, to determine predictors of women’s intentions to attend HPV-CSS in each scenario.

Results 981 of 2016 emailed surveys were completed. Eighty-four percent of women intend to be screened with HPV, which decreased to 54.2% with an extended screening interval, and 51.4% with a delayed start of age 25. Predictors of intention to undergo HPV-CSS screening in Model A were attitudes (OR 1.22; 95% CI 1.15, 1.30), SND (OR 1.02; 95% CI 1.01, 1.03) and PBC (OR 1.16; 95% CI 1.10, 1.22). In Model B, predictors were attitudes (OR 1.32; 95% CI 1.28, 1.37), and in Model C, predictors were attitudes (OR 1.26; 95% CI 1.23, 1.30), education (OR 0.59; 95% CI 0.37, 0.93), and PBC (OR 1.06; 95% CI 1.02, 1.10).

Discussion Women’s intentions to be screened for cervical cancer with HPV decreases substantially with an extended screening interval and delayed screening start. CSS programmes considering primary HPV screening must ensure robust planning to mitigate any negative impact on screening attendance.

Efficacy and safety of intralesional (IL) injection of Mycobacterium w vaccine vs. imiquimod cream in the treatment of anogenital warts: a double blind randomised trial

S Gupta, L Dar, P Kumar, V Sharma, K Verma, S N Dwivedi. All India Institute of Medical Sciences, New Delhi, India

Introduction External Anogenital warts (EGW) are associated with poor response to treatment and high recurrence rates. There is a need for development of immunotherapeutic agents for treatment of AGW.

Objectives To compare efficiency and safety of IL injection of killed Mycobacterium w (Mw) Vaccine and Imiquimod cream in complete resolution of EGWs, recurrence rates, and reduction in HPV viral load.

Method 89 patients (71 male and 18 female) with EGW were recruited over a period of 3 years. Patients were randomised in to two Group: Group A Patients (Male 34, Female 10) received Imiquimod cream and IL placebo injection; Group B patients (Male 37 and female 8) received Placebo cream and IL Mw injections. HPV Genotyping was done by reverse line blot hybridization by the Linear Array (Roche) and viral load was done by Real Time quantitative PCR.

Results Mean percentage reduction in Imiquimod and Mw groups were 84.7% and 83.2%, respectively (P > 0.05). Overall, 59% and 66.7% of patients in Imiquimod and Mw groups respectively showed complete clearance. There was no significant difference in adverse events and recurrence rates. HPV DNA was detected in anogenital warts samples in 84 (94.3%) of 89 patients. The predominant types were HPV-6(55%), 11(41.5%) followed by HPV 16(5.6%), 18(4.4%), and others(27.5%). 22(24.7%) showed infection by multiple HPV types. Baseline HPV 6 and 11 DNA load ranges were 1.4 × 102–2.1 × 108 and 2.6 × 102–2.1 × 108 copies/mg, respectively (P value < 0.001). After treatment, there was a significant decline in viral load of HPV 6 in both the groups, but of HPV 11 only in Mw group.

Conclusions There was no significant difference in efficacy and adverse events in both the treatments. HPV viral load declined significantly and correlated with clinical resolution. Further studies are needed to explore whether injection Mw works for patients who do not respond to topical imiquimod.

Human papillomavirus (HPV) genotypes associated with persistent HSIL isolated by laser capture microdissection

A M Cornall, D Roberts, M Garland, R J Hillman, M Poyten, F Jin, A E Gulich, T S N Tabrizi, on behalf of the SPANC study team. Regional HPV Labnet Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women’s Hospital, Parkville, Victoria, Australia; Murdoch Children’s Research Institute, Parkville, Victoria, Australia; Cytology Department, Douglass Hartley Moir, Macquarie Park, New South UK, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia; The Western Sydney Sexual Health Centre, University of Sydney, Westmead Hospital, Westmead, New South UK, Australia; ‘HPV Epidemiology and Prevention Program, The Kirby Institute, University of New South UK, Sydney, New South Australia

Background Anal squamous cell carcinoma (ASCc) is preceded by persistent high-grade squamous intraepithelial lesion (HSIL). A small proportion of HSIL will progress to ASCc, estimates in men who have sex with men (MSM) suggest one in 400 per year in HIV-positive men and one in 4,000 per year in HIV-negative men. There are no tests to predict which HSIL are more likely to persist and potentially progress to ASCc. As MSM are often concurrently infected with multiple anal HPV genotypes, the role of each in progression to ASCc is unclear.

Methods Biopsies of suspected HSIL collected during high-resolution anoscopy from participants enrolled in the ongoing SPANC cohort of homosexual men (Sydney, Australia) between November 2010 and December 2011. Samples taken at 0, 6 and 12 months were formalin-fixed, paraffin-embedded then sandwich sectioned. Sections 1 and 5 were stained (haematoxylin and eosin (H&E)) and section 2 placed on a PEN-membrane slide. H&E sections were reviewed and lesions annotated using Aperio ScanScope software. Annotated abnormal tissue was isolated using laser capture microdissection (LCM), DNA was extracted and HPV genotypes present determined by reverse hybridisation assay (HPV SPF10-LF/A25, Labo Bio-medical Products).

Results From a pilot study comprising 16 men diagnosed with HSIL at one or more visits, 94% were positive for at least one HPV type. HPV16 was the most common genotype detected in HSIL (28%), followed by 45, 18 (each 17%), 58 (11%), 56, 31, 52, 34 and 33 (each 6%). Three participants had HSIL that persisted over three consecutive visits, 2 were positive for HPV16 and 1 for HPV18. An additional 26% of HSIL persisted for 2 consecutive visits, and were positive for HPV58 (40%), 16, 18 or 33 (each 20%).

Conclusion Overall, 10% of HSIL persisted for longer than 12 months with HPV16 being present in majority of these.
Background HIV acquisition is fueled by infection with HSV-2 and HPV. Microbicides that target all three STIs may more effectively limit HIV incidence. We previously showed that a gel containing the NNRTI MIV-150, zinc acetate (Z) and carrageenan (C, MZC) significantly protected macaques against vaginal SHIV-RT challenge, while ZC also protected mice against HSV-2 vaginally and rectally. Here we evaluate a new formulation of MZC optimised for clinical use against SHIV-RT, HSV-2, and HPV.

Methods Toxicity was measured using the HSV-2 increased susceptibility model in mice. Macaques received gels vaginally every day for 14d followed by SHIV-RT (10^5 TCID_50) 8 or 24h post-last gel or SHIV-RT plus HSV-2 (2 x 10^6 pfu) 8h post-last gel. Rectally, gels were applied 1h before SHIV-RT. Anti-HSV-2 and anti-HIV-16 fV activities were assessed by vaginally or rectally challenging mice with different viral doses 24h before to 8h after single gel application. Significance was assessed by Fisher’s exact or Mann Whitney U tests (P < 0.05).

Results MZC pretreatment did not enhance HSV-2 infection of mice. MZC protected macaques against vaginal SHIV-RT infection (in the presence or absence of HSV-2) for up to 8h (P < 0.0001 vs. C) and rectal SHIV-RT infection (0/5 MZC infected vs. 1/4 C; barrier effect). While MZC only reduced vaginal HSV-2 infection of macaques by 27% after challenge with 2 x 10^6 pfu, MZC significantly reduced vaginal (P < 0.0001) and rectal (P = 0.0187) HSV-2 infection of mice when 10^6 pfu were applied immediately and also when 5 x 10^6 pfu were applied between 8h before and 2h after vaginal challenge (P < 0.0021). Protection of mice against HIV-16 fV was significant (P < 0.0001 vs. HEC) for MZC applied up to 24h before and 2h after challenge.

Conclusion MZC provides a durable window of protection against SHIV-RT, HSV-2, and HPV in vivo, making MZC an excellent candidate microbicide for clinical use.

011.1 \*HERPES SIMPLEX VIRUS (HSV) INFECTION IN THE VOICE (MTN 003) STUDY: PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV WITH DAILY USE OF ORAL TENOFOVIR, ORAL TENOFOVIR-EMTRICITABINE, OR VAGINAL TENOFOVIR GEL

011.2 \*SEXUAL BEHAVIOUR OF HETEROSEXUAL MEN AND WOMEN RECEIVING ANTIRETROVIRAL PRE-EXPOSURE PROPHYLAXIS FOR HIV PREVENTION: POST-UNBLINDING ANALYSIS OF THE PARTNERS PREP STUDY

011.3 \*USING HCV INCIDENCE TRENDS TO DISENTANGLE THE LIKELY IMPACT OF HIV ANTI-RETROVIRAL TREATMENT ON DECREASING HIV INCIDENCE AMONGST INJECTING DRUG USERS: A MODELLING ANALYSIS